| Primary |
| Drug Use For Unknown Indication |
26.9% |
| Tuberculosis |
17.0% |
| Unevaluable Event |
13.3% |
| Bronchitis |
6.2% |
| Sinusitis |
5.8% |
| Pulmonary Tuberculosis |
5.0% |
| Acute Sinusitis |
4.8% |
| Disseminated Tuberculosis |
4.6% |
| Meningitis |
3.1% |
| Lung Disorder |
2.1% |
| Myoclonus |
1.9% |
| Mycobacterial Infection |
1.7% |
| Hypertension |
1.4% |
| Chronic Obstructive Pulmonary Disease |
1.0% |
| Cough |
1.0% |
| Headache |
1.0% |
| Atypical Mycobacterial Infection |
0.8% |
| Device Related Infection |
0.8% |
| Diabetes Mellitus |
0.8% |
| Infection |
0.8% |
|
| Weight Decreased |
10.8% |
| Urticaria |
9.2% |
| Vertigo |
7.7% |
| Renal Failure |
6.2% |
| Sudden Death |
6.2% |
| Visual Acuity Reduced |
6.2% |
| Aplasia Pure Red Cell |
4.6% |
| Electroencephalogram Abnormal |
4.6% |
| Haemorrhage |
4.6% |
| Hallucination, Visual |
4.6% |
| Polyneuropathy |
4.6% |
| Rash Maculo-papular |
4.6% |
| Renal Tubular Disorder |
4.6% |
| Agranulocytosis |
3.1% |
| Bone Infarction |
3.1% |
| Cytolytic Hepatitis |
3.1% |
| Dermatitis Psoriasiform |
3.1% |
| Fall |
3.1% |
| Hepatic Encephalopathy |
3.1% |
| Ligament Rupture |
3.1% |
|
| Secondary |
| Drug Use For Unknown Indication |
23.1% |
| Tuberculosis |
22.4% |
| Bronchitis |
11.2% |
| Pulmonary Tuberculosis |
5.8% |
| Product Used For Unknown Indication |
5.6% |
| Prophylaxis |
4.9% |
| Hiv Infection |
4.4% |
| Mycobacterial Infection |
4.4% |
| Epilepsy |
2.3% |
| Atypical Mycobacterial Infection |
2.1% |
| Antibiotic Prophylaxis |
1.9% |
| Pneumonia Legionella |
1.6% |
| Disseminated Tuberculosis |
1.4% |
| Hypertension |
1.4% |
| Infection |
1.4% |
| Mycobacterium Avium Complex Infection |
1.4% |
| Unevaluable Event |
1.4% |
| Infective Exacerbation Of Chronic Obstructive Airways Disease |
1.2% |
| Cerebral Disorder |
0.9% |
| Liver Disorder |
0.9% |
|
| Tendon Pain |
21.1% |
| Vomiting |
9.2% |
| Cytolytic Hepatitis |
6.6% |
| Sudden Death |
6.6% |
| Malaise |
5.3% |
| Tachycardia |
5.3% |
| Electroencephalogram Abnormal |
3.9% |
| Nervous System Disorder |
3.9% |
| Neutropenia |
3.9% |
| Pyrexia |
3.9% |
| Toxic Skin Eruption |
3.9% |
| Transaminases Increased |
3.9% |
| Weight Decreased |
3.9% |
| Gait Disturbance |
2.6% |
| Immune Reconstitution Syndrome |
2.6% |
| Optic Neuritis |
2.6% |
| Overdose |
2.6% |
| Rash Morbilliform |
2.6% |
| Synovitis |
2.6% |
| Ventricular Extrasystoles |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
27.5% |
| Tuberculosis |
19.6% |
| Hiv Infection |
18.4% |
| Pulmonary Tuberculosis |
6.3% |
| Mycobacterium Avium Complex Infection |
3.2% |
| Antifungal Prophylaxis |
2.5% |
| Arthritis Infective |
2.5% |
| Disseminated Tuberculosis |
2.5% |
| Multiple Myeloma |
2.5% |
| Osteomyelitis |
2.5% |
| Vitamin D Deficiency |
1.9% |
| Cytomegalovirus Infection |
1.6% |
| Arthropathy |
1.3% |
| Bone Disorder |
1.3% |
| Diarrhoea |
1.3% |
| Pain |
1.3% |
| Acquired Immunodeficiency Syndrome |
0.9% |
| Chronic Hepatitis C |
0.9% |
| Prophylaxis |
0.9% |
| Rheumatoid Arthritis |
0.9% |
|
| Pancreatitis Acute |
10.0% |
| Pneumonia Influenzal |
10.0% |
| Renal Failure |
10.0% |
| Aplasia Pure Red Cell |
7.5% |
| Pyrexia |
7.5% |
| General Physical Health Deterioration |
5.0% |
| Hepatitis Fulminant |
5.0% |
| Immune Reconstitution Syndrome |
5.0% |
| Neutropenia |
5.0% |
| Urticaria |
5.0% |
| Venous Thrombosis |
5.0% |
| Vomiting |
5.0% |
| Anaphylactic Shock |
2.5% |
| Anaphylactoid Reaction |
2.5% |
| Drug Eruption |
2.5% |
| Lung Disorder |
2.5% |
| Nephrolithiasis |
2.5% |
| Nervous System Disorder |
2.5% |
| Neuropathy Peripheral |
2.5% |
| Pancytopenia |
2.5% |
|
